ArticleBMC cancer2026
Overexpression of COL10A1 in extracellular matrix predicts poor outcome and promotes ovarian cancer progression.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundOvarian cancer (OC) represents one of the most lethal gynecological malignancies. Extracellular matrix is present in both primary and metastatic tumors and exhibit significant functional heterogeneity, adaptability and resilience. These cells are crucial for cancer progression because of their complex signaling interactions with different cell types in the tumor microenvironment. The collagen type X alpha 1 chain (COL10A1) is notably overexpressed in extracellular matrix and is closely associated with the initiation and progression of the disease. However, the role of the COL10A1 gene in extracellular matrix remains unexplored.
methodsHere, we identified the differentially expressed gene COL10A1 via multiple databases, including the GEO database and the TCGA-OV dataset. We subsequently performed further bioinformatics analyses concerning COL10A1. The external datasets were ultimately analyzed, and clinical samples were collected and examined via immunohistochemistry and quantitative reverse transcription polymerase chain reaction (qRT‒PCR).
resultsOur findings revealed that COL10A1 expression was markedly elevated in OC extracellular matrix and correlated with adverse clinicopathological characteristics and poorer patient prognosis. Functional enrichment analyses indicated that COL10A1 may facilitate tumorigenesis and progression by modulating several pathways associated with cellular growth, metabolism, proliferation, and survival, particularly the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway and extracellular matrix (ECM)-receptor interactions. Furthermore, we observed that COL10A1 was associated with the infiltration of various immune cells and immune checkpoints. Importantly, in clinical samples, COL10A1 expression was significantly increased in OC, which was related to unfavorable clinicopathological features and poorer patient prognosis.
conclusionsOur research indicates that extracellular matrix with elevated COL10A1 expression may enhance OC progression through the modulation of macrophage. Consequently, COL10A1 may serve as a novel biomarker for predicting OC prognosis and provides a promising avenue for developing therapeutic strategies targeting the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.